- Home
- / Bridge Biotherapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Bridge Biotherapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩4.6 K
2024-10-29
Market Capitalization
₩212.1 B
2024-10-29
Revenue
₩2.2 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 11, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|
| Revenue | 58.3B | 6.3B | 1.9B | 3.0B | 100.0M | 2.2M |
| Cost of goods sold | 34.0B | 6.7B | 194.6M | 66.7M | ||
| Gross profit | 24.4B | (339.2M) | 1.7B | 4.1B | 64.5M | 13.2M |
| Gross profit margin, % | 41.8% | -5.4% | 90.2% | 135.3% | 64.5% | 605.0% |
| Operating expense total | 23.2B | 18.9B | 27.7B | 53.8B | 39.0B | 17.6B |
| Depreciation and amortization | 451.4M | 357.9M | 381.5M | 1.1B | 1.4B | 2.0B |
| EBITDA | 1.2B | (19.2B) | (26.0B) | (49.7B) | (38.9B) | (17.6B) |
| EBITDA margin, % | 2.0% | -303.2% | -1351.4% | -1643.2% | -38893.9% | -806507.7% |
| EBIT | 584.2M | (19.7B) | (26.7B) | (50.8B) | (40.3B) | (19.5B) |
| EBIT margin, % | 1.0% | -311.2% | -1387.0% | -1678.9% | -40320.5% | -896212.9% |
| Interest income | 140.6M | 208.7M | 350.7M | 951.0M | 1.0B | 421.4M |
| Interest expense | 2.7B | 6.3M | 7.5M | 64.8M | 170.6M | 188.8M |
| Pre tax profit | 7.2B | (19.2B) | (26.3B) | (50.0B) | (42.5B) | (19.9B) |
| Income tax expense | 5.9B | |||||
| Net Income | 1.3B | (19.2B) | (26.3B) | (50.0B) | (42.5B) | (19.9B) |